Prem Chandran, MD
Nephrology · Des Moines, IANPI 1518969104
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,858 of the $18,837 with a category attached, or 73.6%. 27 manufacturers reported payments, led by AstraZeneca at 51.9% of the total. Reporting peaked in 2024 at $11,144 and has fallen 86.2% since, to $1,535 in 2025. Among nephrology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $169.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Otsuka America Pharmaceutical, Inc.$5K
- Travere Therapeutics, Inc.$2K
- Novartis$405
- Calliditas Therapeutics US Inc.$204
- Amgen$188
- plus $1K from 21 others
Across 1 payment — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covidien LP$300
What the payments were for
- Consulting fees$13,85874%
- Travel & lodging$1,7369%
- Food & beverage$3,10816%
- Education$1351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 18 | $9,769 |
| Otsuka America Pharmaceutical, Inc. | 13 | $5,320 |
| Travere Therapeutics, Inc. | 13 | $1,882 |
| Novartis | 16 | $405 |
| Calliditas Therapeutics US Inc. | 4 | $204 |
| Amgen(2 entities) | 10 | $188 |
| Mallinckrodt Enterprises LLC | 4 | $144 |
| Vifor Pharma, Inc. | 6 | $139 |
| Madrigal Pharmaceuticals | 1 | $133 |
| Boehringer Ingelheim | 6 | $118 |
| Immucor, Inc. | 1 | $113 |
| Bayer | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Veloxis Pharmaceuticals, Inc. | 1 | $38 |
| Pfizer | 2 | $33 |
| Cormedix Inc. | 1 | $31 |
| Genentech USA, Inc. | 1 | $30 |
| Baxter Healthcare | 1 | $26 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Amicus Therapeutics, Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| OPKO Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,837 in reported general payments places this provider in the 90th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 13 | $5,654 |
| Potassium Chloride | 47 | $2,749 |
| Doxazosin Mesylate | 130 | $2,373 |
| Magnesium SulfateMagnesium Sulfate In Water | 14 | $784 |
| Tacrolimus | 12 | $586 |
| SynthroidLevothyroxine Sodium | 12 | $576 |
| Calcium Acetate | 18 | $570 |
| Bumetanide | 38 | $567 |
| Losartan Potassium | 50 | $473 |
| Metoprolol Succinate | 18 | $440 |
| Tamsulosin Hcl | 17 | $343 |
| Amlodipine Besylate | 54 | $325 |
| Metolazone | 29 | $315 |
| Furosemide | 66 | $248 |
| Carvedilol | 19 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $9,769 | $5,65413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 nephrology providers in Iowa.
Other nephrology in Des Moines
- Craig ShadurDes Moines$314K
- Mark BelzDes Moines$2K
- Jobinson ThomasDes Moines$2K
- Arsalan AlviDes Moines$1K
- Robert SmithDes Moines$1K
- Sameer YaseenDes Moines$1K
- Jennifer ThompsonDes Moines$1K
- Dhivya SundaramurthyDes Moines$930
- Arani NanavatiDes Moines$930
- Bruce BuchsbaumDes Moines$702
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.